Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Why now
Thesis: Early oncology ADC data presentation
Catalyst to watch: ENA 2026 presentation results
Main risk: Phase 1 data may underwhelm
Why it matters
An oral presentation slot for early-phase oncology data is a pipeline milestone for a small biotech.
Details
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development....
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-28 11:30 UTC